Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells

Blood

Volumn 116, Issue 20, 2010, Pages 4284-4287

  Lu, Min ^a   Wang, Jiapeng ^a   Li, Yan ^a   Berenzon, Dmitriy ^a   Wang, Xiaoli ^a   Mascarenhas, John ^a   Xu, Mingjiang ^a   Hoffman, Ronald ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ALPHA INTERFERON;

APOPTOSIS; ARTICLE; CD34 SELECTION; CELL CULTURE; CELL LINE; DRUG MECHANISM; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LOW DRUG DOSE; POLYCYTHEMIA VERA; PRIORITY JOURNAL;

EID: 78549243371     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-04-279125     Document Type: Article

References (19)

1. Hoffman R, Xu M, Finazzi G, Barbui T. The polycythemias. In: Hoffman R, Benz EJ Jr, Shattil SJ, et al, eds. Hematology: Basic Principles and Practice. Philadelphia, PA: Churchill Livingstone, 2008:1073-1108.
2. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer. 2006;107(3):451-458.
3. Liu E, Jelinek J, Pastore YD, et al. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood. 2003;101(8):3294-3301. (Pubitemid 36858027)
4. Massaro P, Foa P, Pomati M, et al. Polycythemia vera treated with recombinant interferon-alpha 2a: evidence of a selective effect on the malignant clone. Am J Hematol. 1997;56(2):126-128.
5. Messora C, Bensi L, Vecchi A, et al. Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha. Br J Haematol. 1994;86(2):402-404.
6. Chott A, Gisslinger H, Thiele J, et al. Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis. Br J Haematol. 1990;74(1):10-16. (Pubitemid 20043566)
7. Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood. 2006;108(6):2037-2040.
8. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112(8):3065-3072.
9. Lu M, Zhang W, Li Y, Berenzon D, et al. Interferon alpha targets JAK2V617F positive hematopoietic progenitor cells and acts through the p38 MAP kinase pathway. Exp Hematol. 2010;38(6):472-480.
10. Kiladjian JJ, Chomienne C, Fenaux P. Interferonalpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia. 2008;22(11):1990-1998.
11. Silva M, Richard C, Benito A, Sanz C, Olalla I, Fernández-Luna JL. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med. 1998;338(9):564-571.
12. Ciurea SO, Merchant D, Mahmud N, et al. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood. 2007;110(3):986-993. (Pubitemid 47267438)
13. Garçon L, Rivat C, James C. Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells. Blood. 2006;108(5):1551-1554.
14. Cragg MS, Harris C, Strasser A, Scott CL. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat Rev Cancer. 2009;9(5):321-326.
15. Zeuner A, Pedini F, Francescangeli F, Signore M, Girelli G, Tafuri A, De Maria R. Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells. Blood. 2009;113(7): 1522-1525.
16. Will B, Siddiqi T, Alberich Jordà M, Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. Blood. 2010; 115(14):2901-2909.
17. Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood. 2006;108(9):3128-3134.
18. Ishii T, Xu M, Zhao Y, Hu WY, Ciurea S, Bruno E, Hoffman R. Recurrence of clonal hematopoiesis after discontinuing pegylated recombinant interferon- alpha 2a in a patient with polycythemia vera. Leukemia. 2007;21(2):373-374.
19. Kim BJ, Ryu SW, Song BJ. JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells. J Biol Chem. 2006;281(30):21256-21265.